Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients
The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer wa...
- Autores:
-
Arias-Murillo, Jazmín Roció
Salinas-Nova, María Angélica
Caicedo, Tatiana
Galindo-Borda, Marisol
Meneses-Gil, Ximena
Montero, Camilo
Girón, Fernando
Pedraza, Nestor
Aroca, Gustavo
Ospina-Martínez, Martha Lucía
Mercado-Reyes, Marcela
- Tipo de recurso:
- Fecha de publicación:
- 2023
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/12114
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/12114
https://doi.org/10.1016/j.transproceed.2023.02.034
https://www.sciencedirect.com/science/article/pii/S0041134523000696
- Palabra clave:
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 Internacional
| id |
USIMONBOL2_d233a30f99e09dc06129dfa112c92e9f |
|---|---|
| oai_identifier_str |
oai:bonga.unisimon.edu.co:20.500.12442/12114 |
| network_acronym_str |
USIMONBOL2 |
| network_name_str |
Repositorio Digital USB |
| repository_id_str |
|
| dc.title.eng.fl_str_mv |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients |
| title |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients |
| spellingShingle |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients |
| title_short |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients |
| title_full |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients |
| title_fullStr |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients |
| title_full_unstemmed |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients |
| title_sort |
Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients |
| dc.creator.fl_str_mv |
Arias-Murillo, Jazmín Roció Salinas-Nova, María Angélica Caicedo, Tatiana Galindo-Borda, Marisol Meneses-Gil, Ximena Montero, Camilo Girón, Fernando Pedraza, Nestor Aroca, Gustavo Ospina-Martínez, Martha Lucía Mercado-Reyes, Marcela |
| dc.contributor.author.none.fl_str_mv |
Arias-Murillo, Jazmín Roció Salinas-Nova, María Angélica Caicedo, Tatiana Galindo-Borda, Marisol Meneses-Gil, Ximena Montero, Camilo Girón, Fernando Pedraza, Nestor Aroca, Gustavo Ospina-Martínez, Martha Lucía Mercado-Reyes, Marcela |
| description |
The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity by vaccination, and immunosuppressant type were identified. As a result, of the patients included in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose in patients who had completed the vaccination schedule. Antibody titers were higher in patients with hybrid immunity, and the proportion of nonresponsive patients was higher among those who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only 15% of patients treated with this medicine seroconverted and patients vaccinated with Corona- Vac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines against SARS-CoV-2 was identified in the transplant population, and this response varied with the type of vaccine administered and the immunosuppressive treatment. |
| publishDate |
2023 |
| dc.date.accessioned.none.fl_str_mv |
2023-03-29T21:15:51Z |
| dc.date.available.none.fl_str_mv |
2023-03-29T21:15:51Z |
| dc.date.issued.none.fl_str_mv |
2023 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.spa.spa.fl_str_mv |
Artículo científico |
| dc.identifier.citation.eng.fl_str_mv |
This research was funded by the National Institute of Health, project code CEMIN-19-2021, an investment project strengthening the coordination of blood banks and donation and transplant networks, national code BPIN-2018011000083, and resources of the hospitals with transplant programs participating. |
| dc.identifier.issn.none.fl_str_mv |
18732623 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12442/12114 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.transproceed.2023.02.034 |
| dc.identifier.url.none.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S0041134523000696 |
| identifier_str_mv |
This research was funded by the National Institute of Health, project code CEMIN-19-2021, an investment project strengthening the coordination of blood banks and donation and transplant networks, national code BPIN-2018011000083, and resources of the hospitals with transplant programs participating. 18732623 |
| url |
https://hdl.handle.net/20.500.12442/12114 https://doi.org/10.1016/j.transproceed.2023.02.034 https://www.sciencedirect.com/science/article/pii/S0041134523000696 |
| dc.language.iso.eng.fl_str_mv |
eng |
| language |
eng |
| dc.rights.*.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
pdf |
| dc.publisher.spa.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
Vol. XX No. XX Año 2023 |
| institution |
Universidad Simón Bolívar |
| bitstream.url.fl_str_mv |
https://bonga.unisimon.edu.co/bitstreams/60549288-7175-427c-8db0-80380e0943b3/download https://bonga.unisimon.edu.co/bitstreams/89e126ac-cf76-43d9-834c-083dda8e3796/download https://bonga.unisimon.edu.co/bitstreams/b9486ce4-ef98-4ab9-8086-a50b1fd75df4/download https://bonga.unisimon.edu.co/bitstreams/229500e0-60d3-4a7b-96b3-e7f954d2b20f/download https://bonga.unisimon.edu.co/bitstreams/ce750639-defe-4878-8f4f-8737f4425ec4/download https://bonga.unisimon.edu.co/bitstreams/e55c9068-a06a-4a77-941b-a66148ee4daf/download https://bonga.unisimon.edu.co/bitstreams/40c13a1e-0607-4ff6-9c61-8cedc187d435/download |
| bitstream.checksum.fl_str_mv |
9ea27f2631ca732d584281bc0b793dba 4460e5956bc1d1639be9ae6146a50347 733bec43a0bf5ade4d97db708e29b185 1455fe265814931b789a444f079d97c7 1455fe265814931b789a444f079d97c7 874d77e489dc7159317558676d6dcb3e 874d77e489dc7159317558676d6dcb3e |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Digital Universidad Simón Bolívar |
| repository.mail.fl_str_mv |
repositorio.digital@unisimon.edu.co |
| _version_ |
1812100512442482688 |
| spelling |
Arias-Murillo, Jazmín Roció92dc0e81-028b-498a-84e8-f647ff0eaabcSalinas-Nova, María Angélicaa53281b2-9ab6-4172-b9f6-93e17b5b72ceCaicedo, Tatiana743025da-908f-4376-b208-6e78b3d582a3Galindo-Borda, Marisol4d516cca-b759-474d-887f-1ac48f878c5eMeneses-Gil, Ximena44e3006a-5948-44ab-a3f3-9ab74a33ef44Montero, Camilo065b8673-a76b-4053-a2c0-8cebf5e98c94Girón, Fernandoad1e6e84-6203-4069-a907-7fd2a0c0f294Pedraza, Nestor7a1d7ad2-c87e-40c2-ac44-eec38624e493Aroca, Gustavoe6bdfa35-1a1c-42aa-aee3-89159433d484Ospina-Martínez, Martha Lucía6bf92bb7-1918-4a05-a8b1-4aeed1e28b37Mercado-Reyes, Marcela4051c239-53db-43d2-8387-89d8d2d814e22023-03-29T21:15:51Z2023-03-29T21:15:51Z2023This research was funded by the National Institute of Health, project code CEMIN-19-2021, an investment project strengthening the coordination of blood banks and donation and transplant networks, national code BPIN-2018011000083, and resources of the hospitals with transplant programs participating.18732623https://hdl.handle.net/20.500.12442/12114https://doi.org/10.1016/j.transproceed.2023.02.034https://www.sciencedirect.com/science/article/pii/S0041134523000696The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity by vaccination, and immunosuppressant type were identified. As a result, of the patients included in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose in patients who had completed the vaccination schedule. Antibody titers were higher in patients with hybrid immunity, and the proportion of nonresponsive patients was higher among those who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only 15% of patients treated with this medicine seroconverted and patients vaccinated with Corona- Vac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines against SARS-CoV-2 was identified in the transplant population, and this response varied with the type of vaccine administered and the immunosuppressive treatment.pdfengElsevierAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Vol. XX No. XX Año 2023Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientsinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant 2020;20:1800–8.TagedEndAkalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med 2020;382:2475–7.TagedEndArias-Murillo YR, Benavides-V CA, Salinas-N MA, Osorio- Arango K, Plazas-Sierra C, Cortés JA. SARS-CoV2/COVID-19 infection in transplant recipients and patients on the transplant waiting list in Colombia. Transplant Proc 2021;53:1237–44.TagedEndMagicova M, Zahradka I, Fialova M, et al. Determinants of immune response to anti-SARS-CoV-2 mRNA vaccines in kidney transplant recipients: a prospective cohort study. Transplantation 2022;106:842–52.Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation 2022;106:821–34.Benotmane I, Gautier-Vargas G, Cognard N, et al. Weak anti- SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int 2021;99:1487–9.TagedEndBoyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:2204–6.TagedEndRozen-Zvi B, Yahav D, Agur T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect 2021;27(1173):e1–.e4.TagedEndBenotmane I, Gautier-Vargas G, Cognard N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int 2021;99:1498– 500.TagedEndHaskin O, Ashkenazi-Hoffnung L, Ziv N, et al. Serological response to the BNT162b2 COVID-19 mRNA vaccine in adolescent and young adult kidney transplant recipients. Transplantation 2021;105:e226–33.TagedEndCucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant 2021;21:2727–39.TagedEndBalcells ME, Le Corre N, Dur an J, et al. Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile. Clin Infect Dis 2022;75:e594–602.TagedEndMiele M, Bus a R, Russelli G, et al. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. Am J Transplant 2021;21:2919–21.TagedEndMarinaki S, Adamopoulos S, Degiannis D, et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am J Transplant 2021;21:2913–5.Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 2021;21:2719–26.Hall VG, Ferreira VH, Ierullo M, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am J Transplant 2021;21:3980–9.TagedEndR€ossler A, Riepler L, Bante D, von Laer D, Kimpel J. SARSCoV- 2 omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med 2022;386:698–700.TagedEndEren Sadio glu R, Demir E, Evren E, et al. Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients. Transpl Infect Dis 2021;23:e13740.TagedEndDheir H, Tocoglu A, Toptan H, et al. Short and mid-term SARS-CoV-2 antibody response afterinactivated COVID-19 vaccine in hemodialysis and kidneytransplant patients. J Med Virol 2022;94: 3176–83.TagedEndMariana S, Florencia R, Jose S, et al. Short and mid-term SARS-CoV-2 antibody response afterinactivated COVID-19 vaccine in hemodialysis and kidneytransplant patients. Clin Kidney J 2022;15: 527–33.Bruminhent J, Setthaudom C, Chaumdee P, et al. SARS-CoV- 2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study). Am J Transplant 2022;22:813–22.Seija M, Rammauro F, Santiago J, et al. Short and mid-term SARS-CoV-2 antibody response afterinactivated COVID-19 vaccine in hemodialysis and kidney transplant patients. Clin Kidney J 2022;15: 527–33.TagedEndCorreia AL, Leal R, Pimenta AC, et al. The type of SARSCoV- 2 vaccine influences serological response in kidney transplant recipients. Clin Transplant 2022;36:e14585.TagedEndPrendecki M, Thomson T, Candice L, et al. Willicombe M in collaboration with the OSC. Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines. medRxiv, in press.Gangappa S, Wrammert J, Wang D, et al. Kinetics of antibody response to influenza vaccination in renal transplant recipients. Transpl Immunol 2019;53:51–60.TagedEndOu MT, Boyarsky BJ, Chiang TPY, et al. Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking Belatacept. Transplantation 2021;105:2119–23.Chavarot N, Ouedrani A, Marion O, et al. Poor anti-SARSCoV- 2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with Belatacept. Transplantation 2021;105:e94–5.TagedEndAbravanel F, Marion O, Del Bello A, et al. Humoral and cellular immune responses of solid organ transplant patients on Belatacept to three doses of mRNA-based anti-SARS-CoV-2 vaccine. Vaccines (Basel) 2022;10:354.TagedEndNoble J, LangelloA, Bouchut W, Lupo J, Lombardo D, Rostaing L. Immune response post−SARS-CoV-2 mRNA vaccination in kidney transplant recipients receiving Belatacept. Transplantation 2021;105:e259–60.Hammerman A, Sergienko R, Friger M, et al. Effectiveness of the BNT162b2 vaccine after recovery from Covid-19. N Engl J Med 2022;386:1221–9.ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf731467https://bonga.unisimon.edu.co/bitstreams/60549288-7175-427c-8db0-80380e0943b3/download9ea27f2631ca732d584281bc0b793dbaMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/89e126ac-cf76-43d9-834c-083dda8e3796/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/b9486ce4-ef98-4ab9-8086-a50b1fd75df4/download733bec43a0bf5ade4d97db708e29b185MD53TEXT1-s2.0-S0041134523000696-main.pdf.txt1-s2.0-S0041134523000696-main.pdf.txtExtracted texttext/plain43442https://bonga.unisimon.edu.co/bitstreams/229500e0-60d3-4a7b-96b3-e7f954d2b20f/download1455fe265814931b789a444f079d97c7MD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain43442https://bonga.unisimon.edu.co/bitstreams/ce750639-defe-4878-8f4f-8737f4425ec4/download1455fe265814931b789a444f079d97c7MD56THUMBNAIL1-s2.0-S0041134523000696-main.pdf.jpg1-s2.0-S0041134523000696-main.pdf.jpgGenerated Thumbnailimage/jpeg5820https://bonga.unisimon.edu.co/bitstreams/e55c9068-a06a-4a77-941b-a66148ee4daf/download874d77e489dc7159317558676d6dcb3eMD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5820https://bonga.unisimon.edu.co/bitstreams/40c13a1e-0607-4ff6-9c61-8cedc187d435/download874d77e489dc7159317558676d6dcb3eMD5720.500.12442/12114oai:bonga.unisimon.edu.co:20.500.12442/121142024-08-14 21:53:57.309http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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 |